For research teamsHelp me find a study
Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,753-1,764 of 4,306
Drug study icon
CompletedEUCTR 2012-003996-20

A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects with Stable Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.
Countries
Bulgaria
Sponsor
Alkermes, Inc.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2012-003445-15

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects with Acute Exacerbation of Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria
Sponsor
Alkermes, Inc.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2011-002513-11

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed dose OPC-34712 (4, 2, and 1 mg/day) in the Treatment of Adults With Acute Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Slovakia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Slovakia
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2011-002538-38

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Latvia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Latvia, Poland
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2016-003437-18

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (Enhance-2)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Germany
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Germany
Sponsor
ACADIA Pharmaceuticals Inc.
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2011-002292-41

A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients with DSM-IV-TR Schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Greece
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Greece
Sponsor
Eli Lilly and Company
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2007-002160-10

A prospective, open-label, single arm, multinational, multi-centre, flexible dose, extension study of the SCoP 99824 with sertindole for patients suffering from schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
View study
Drug study icon
TerminatedEUCTR 2008-007800-27

A Prospective, Randomized, Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate with Oral Risperidone in Adults with Recently-Diagnosed Schizophrenia...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Bulgaria, Czechia
Sponsor
Janssen-Cilag International NV
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2008-000479-11

A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, Czechia, Spain
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2008-001441-26

A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
France, Belgium, Germany, ...
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2004-003340-22

A randomised, placebo controlled, double blind trial of asenapine in the prevention of relapse after long term treatment of schizophrenia.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Latvia
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Latvia
Sponsor
Pfizer Luxembourg SARL Latvia Branch
Condition
Schizophrenia
View study
Drug study icon
CompletedEUCTR 2014-002176-83

A randomized trial administering Sodium Nitroprusside vs. placebo as add-on to antipsychotics in patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Romania
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrug
Countries
Romania
Sponsor
Clinirx Tangent Research
Condition
Schizophrenia
View study
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.